Abstract
Background: Hypogonadism in male patients with diabetes mellitus is associated with older age, obesity and poor glycaemic control. The patterns of sperm count, testicular volume, sperm motility and morphology have also been reported to be abnormal in these patients, though reports are conflicting. The objectives of this study were to assess gonadal function and sperm parameters in Nigerian males with diabetes mellitus.
Methods: A study sample of 150 males consisting of 108 patients and 56 age-matched controls were recruited. The ADAM questionnaire was used to obtain a clinical score for hypogonadism. Laboratory parameters measured were fasting plasma glucose, serum LH, FSH, free testosterone, total cholesterol, LDL, HDL and triglyceride. Testicular volume was measured with a Prader orchidometer. Total sperm count, sperm morphology and motility were assessed.
Results: Hypogonadism was present in 38.9% of males with diabetes compared to 3.6% in controls. The patients with diabetes had significantly lower sperm count, reduced sperm motility with increased abnormal forms than the controls (p<0.001, p<0.001). Only 8.5% of the patients did not demonstrate any abnormality in testicular function.
Conclusion: Poor sperm function was more common than hypogonadism and was associated with poor glycaemic control (p<0.001). Likewise, hypogonadism was significantly associated with poor glycaemic control (p<0.001).
Keywords: Hypogonadism, type 2 diabetes, males, glycaemic control, sperm function, Nigeria.
Current Diabetes Reviews
Title:Testicular Dysfunction is a Common Feature in Men with Type 2 Diabetes Mellitus in a Nigerian Tertiary Hospital
Volume: 14 Issue: 3
Author(s): Onung Samuel Inih, Young Ekenechukwu Esther*, Fasanmade Olufemi Adetola, Anyanwu Anthony Chinedu, Nwatu Chidinma Brenda and Ohwovoriole Augustine Efedaye
Affiliation:
- Department of Medicine, University of Nigeria, Ituku-Ozalla, Enugu,Nigeria
Keywords: Hypogonadism, type 2 diabetes, males, glycaemic control, sperm function, Nigeria.
Abstract: Background: Hypogonadism in male patients with diabetes mellitus is associated with older age, obesity and poor glycaemic control. The patterns of sperm count, testicular volume, sperm motility and morphology have also been reported to be abnormal in these patients, though reports are conflicting. The objectives of this study were to assess gonadal function and sperm parameters in Nigerian males with diabetes mellitus.
Methods: A study sample of 150 males consisting of 108 patients and 56 age-matched controls were recruited. The ADAM questionnaire was used to obtain a clinical score for hypogonadism. Laboratory parameters measured were fasting plasma glucose, serum LH, FSH, free testosterone, total cholesterol, LDL, HDL and triglyceride. Testicular volume was measured with a Prader orchidometer. Total sperm count, sperm morphology and motility were assessed.
Results: Hypogonadism was present in 38.9% of males with diabetes compared to 3.6% in controls. The patients with diabetes had significantly lower sperm count, reduced sperm motility with increased abnormal forms than the controls (p<0.001, p<0.001). Only 8.5% of the patients did not demonstrate any abnormality in testicular function.
Conclusion: Poor sperm function was more common than hypogonadism and was associated with poor glycaemic control (p<0.001). Likewise, hypogonadism was significantly associated with poor glycaemic control (p<0.001).
Export Options
About this article
Cite this article as:
Inih Samuel Onung , Esther Ekenechukwu Young *, Adetola Olufemi Fasanmade, Chinedu Anthony Anyanwu , Brenda Chidinma Nwatu and Efedaye Augustine Ohwovoriole, Testicular Dysfunction is a Common Feature in Men with Type 2 Diabetes Mellitus in a Nigerian Tertiary Hospital, Current Diabetes Reviews 2018; 14 (3) . https://dx.doi.org/10.2174/1573399813666170425152046
DOI https://dx.doi.org/10.2174/1573399813666170425152046 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Retrospective, Observation Study: Quantitative and Qualitative Effect of Ezetimibe and HMG-CoA Reductase Inhibitors on LDL-Cholesterol: Are There Disappearance Thresholds for Small, Dense LDL and IDL?
Recent Patents on Cardiovascular Drug Discovery Is Alzheimers Disease a Myth? When is Disease a Disease?
Current Alzheimer Research Modern Therapeutic Strategies for Autoimmune Diseases
Current Pharmaceutical Design Meet Our Editorial Board Member:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Neonatal Fc Receptor and its Role in the Absorption, Distribution, Metabolism and Excretion of Immunoglobulin G-Based Biotherapeutics
Current Drug Metabolism Molecular Basis of Inflammation and Insulin Resistance in Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery Clinical Experience with the Use of Angiotensin Receptor Blockers in Patients with Cardiovascular, Cerebrovascular and Renal Diseases
Current Clinical Pharmacology Targeting Dyslipidemia in the Metabolic Syndrome: An Update
Current Vascular Pharmacology Molecular Prevalence and Risk Factors of Gastroesophageal Reflux Disease in Hemodialysis Patients
Current Signal Transduction Therapy Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema – An Overlooked Adverse Drug Reaction?
Current Diabetes Reviews Effectors of Fatty Acid Oxidation Reduction: Promising New Anti-Ischaemic Agents
Current Pharmaceutical Design Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Immunogenetic Mechanisms Leading to Thyroid Autoimmunity: Recent Advances in Identifying Susceptibility Genes and Regions
Current Genomics Targeting Nrf2 in Protection Against Renal Disease
Current Medicinal Chemistry Wnt Signaling in Development, Disease and Translational Medicine
Current Drug Targets Perioperative Glycemic Management in Insulin Pump Patients Undergoing Noncardiac Surgery
Current Pharmaceutical Design Recent Advances in Antiarrhythmic Drug Treatment of Atrial Fibrillation
Recent Patents on Cardiovascular Drug Discovery Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition
Reviews on Recent Clinical Trials Hypertension to Heart Failure: New Developmental Strategies do not Cross a Clinical and Therapeutic Divide
Current Pharmaceutical Design